Proliposomes: An Approach for the Development of Stable Liposome
DOI:
https://doi.org/10.30827/ars.v60i4.8517Keywords:
Liposome, Proliposome, Stability, Bioavailability, Phospholipid, CholesterolAbstract
Background: For several years, many attempts have been made for the improvement of liposomal stability. In 1986, Payne et al, introduced the concept of Pro-liposome for liposome preparation in order to avoid physicochemical instability encountered in some liposome suspensions such as aggregation, fusion, hydrolysis, and/or oxidation.
Objective: The objective of this review is to focus on different aspects related to Proliposomes, their method of preparation, characterization techniques and pointing out its scope in drug delivery systems.
Methods: Proliposomes are a new form of drug delivery systems. They are dry, free-flowing granular products composed of drug and phospholipid which, upon addition of water, disperse to form a multi-lamellar liposomal suspension.
Results and Discussion: These Proliposomes are nearly as good as or perhaps better than conventional liposomes. In the present review attempt has been made to briefly explain the concept of Proliposomes with a focus on its components, preparation, characterizations and their field of application.
Conclusion: Extensive survey of literatures and collected data suggests that Pro-liposomes are promising drug carriers for the future.
Downloads
References
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei, M, Kouhi M, NejatiKoshki K. Liposome: Classification, preparation, and applications. Nanoscale Res. Lett 2013; 8(1): 102-108.
Vyas SP, Khar RK. Liposome. In Vyas SP. Targeted and controlled drug delivery (Novel carrier systems). 2nd ed. CBS publishers and distributors, New Delhi; 2006. p.173- 181.
New RRC. Preparation of liposomes. In New RRC. Liposomes: a practical approach, 2nd ed. IRL Press: Oxford; New York; 1990. p.36-39.
Parmar G, Bala R, Seth N, Banerjee A. Proliposome: Novel drug delivery system. World J Pharm Res 2015; 4(7): 679-692.
Muneer S, Masood Z, Butt S, Anjum S, Zainab H. Proliposomes as Pharmaceutical Drug Delivery System: A Brief Review. J Nanomed Nanotechnol 2017; 8: 448-450.
Payne NI, Browning I, Hynes CA. Characterization of proliposomes. J. Pharm. Sci 1986; 75(4): 330-333.
Hiremath R, Gowda D, Raj A, Shamant BS, Srivastava A. Proliposomes: A novel approach to carrier drug delivery system. J Chem Pharm Res 2016; 8: 348-354.
Chaumeil JC. Micronization: A method of improving the bioavailability of poorly soluble drugs. Methods Find Exp. Clin. Pharmacol 1998; 20(3): 211-215.
Chen CM, Alli, D. Use of fluidized bed in proliposome manufacturing. J. Pharm. Sci 1987; 76: 419-420.
Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul 1995; 12(3): 229-246.
Rong LJBC, Sophia YL. Liposomes in solubilisation. In Water-Insoluble drug formulation, 2nd ed.; Liu, R., Ed. CRC Press: Boca Raton, FL, USA; 2008. p. 375-416.
Betageri GV, Jenkins SA, Parsons DL. Liposome drug delivery systems. Technomic Pub. Lancaster; 1993. p.135.
Gupta V, Barupal AK, Ramteke S. Formulation development and in vitro characterization of proliposomes for topical delivery. Indian J Pharm Sci 2008; 70: 768-775.
Shruthi MV, Parthiban S, Senthilkumar GP, Tamizmani T. Evaluation of potential hypoglycemic activity of proliposomal gel containing Metformin hydrochloride. Asian J Res Biol Pharm Sci 2014; 2(2):77-88.
Alves GP, Santana MHA. Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties. Pow Tech 2004; 145: 139-148.
Shaji J, Bhatia V. Proliposomes: A brief overview of novel delivery system, Int Pharm Bio Sci 2013; 4(1): 150-160.
F Xia; D Hu; H jin; Y Zhao; J Liang. Food Hydrocolloids 2012: 456-463.
X Fei; J Heyang; Z Yaping; G Xinqiu. Supercritical antisolvent-based technology for preparation of vitamin D3 proliposome and its characteristics. Chinese J Chem Eng 2011;19(6): 1039-1046.
Song KH, Chung SJ, Shim CK. Preparation and evaluation of proliposomes containing salmon calcitonin. Journal of Controlled Release 2002; 84: 27-37.
Leigh M. Supra Vail Vaginal Gel. In: Michael J. Rathbone, Jonathan Hadgraft, Michael S. Roberts (eds.), Modified-Release Drug Delivery Technology, Marcel Dekker, NewYork; 2003. p. 791-800.
Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgesterel for effective contraception. J Control Release 1998; 54:149–65.
Potluri, P, Betageri GV. Mixed-micellar proliposomal systems for enhanced oral delivery of progesterone. Drug Deliv 2006; 13(3): 227-232.
Bobbala SK, Veerareddy PR. Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery. J. Liposome Res 2012; 22(4): 285-294.
Vemuri S, Rhodes C. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Ac Hel 1995; 70: 95-111.
Riaz, M. Liposomes preparation methods. Pak. J. Pharm. Sci 1996; 9(1): 65-77.
Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54:131–155.
Katare OP.; Vyas SP, Dixit VK. Proliposomes of indomethacin for oral administration. J. Microencapsul 1991; 8(1): 1-7.
Yadav A, Murthy MS, Shete AS, Sakhare S. Stability aspects of liposomes. Ind J Pha Edu Res 2011; 45: 402-413.
Chu C, Tong SS, Xu Y, Wang L. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo. Acta Pharmacol Sin 2011; 32(7): 973-980.
Dhurke R, Nalla P, Bagam S, Eedara BB. Formulation and evaluation of domperidone oral proliposomal powders. Int J PharmTech Res 2015; 7(1):108-118
Chuandi Sun, Ji Wang, Jianping Liu, Wenli zhang. Liquid proliposomes of Nimodipine drug delivery system: Preparation, characterization, and pharmacokinetic. AAPS Pharm Sci Tech 2013;14(1):332-338.
Deo MR, Sant VP, Parekh SR, Khopade AJ, Banakar UV. Proliposome-based transdermal delivery of levonorgestrel. J Biomat App 1997; 12:77–88.
Jukanti R, Sheela S, Bandari S, Veerareddy PR. Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. J Pharm Sci 2011; 100: 3208-3222.
Jain SK, Jain NK. Controlled and novel drug delivery. CBS publishers and distributors, Delhi 2003: 304-341.
Hwang BY, Jung BH, Chung SJ, Lee MH, Shim CK. In vitro skin permeation of nicotine from proliposomes. J Control Release 1997; 49: 177-184.
Kumara BC, Parthiban S, Senthil Kumar GP, Tamiz Mani T, Formulation and Evaluation of Proliposomal Gel Containing Repaglinide Using Mannitol as Water Soluble Carrier. Imperial Journal of Interdisciplinary Research 2016; 2(5):1777-1786.
Kurakula M, Srinivas C, Kasturi N, Diwan PV. Formulation and Evaluation of Prednisolone Proliposomal Gel for Effective Topical Pharmacotherapy. Int J Pharm Sci Drug Res 2012; 4(1):35-43.
Kurakula M, Pasula, N. Piroxicam proliposomal gel -A novel approach for topical delivery. J Pharm Res 2012;5 (3):1755.
Ning MY, Guo YZ, Pan HZ, Yu HM. Preparation and evaluation of proliposomes containing Clotrimazole. Chem Pharm bull, 2005; 53(6):620-624.
Chougule M, Padhi BJ, Misra A. Development of Spray Dried Liposomal Dry Powder Inhaler of Dapsone. AAPS Pharm Sci Tech 2008, 9(1), 47-53.
Kaur PI, Garg A, Singla KA. Vesicular systems in ocular drug delivery: an overview. Int J Pharm 2004; 269: 1- 14.
Karn PR, Kim HD, Kang H, Sun BK, Jin SE, Hwang SJ. Preparation and evaluation of cyclosporin a-containing proliposomes: a comparison of the supercritical antisolvent process with the conventional film method. Int J Nanomed 2014:9 5079–5091.
Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomed 2009; 4: 299–319.
Rojanarat W, Nakpheng T, Thawithong E, Yanyium N. Levofloxacin-Proliposomes: Opportunities for use in lung Tuberculosis. Pharmaceutics 2012; 4:385-412.
Patil A, Pokharkar GV. Single step spray drying method to develop proliposomes for inhalation: A systematic study based on quality by design approach. Pulmonary Pharmacol Therapeutics 2014; 27(2):197-207.
Kajornwongwattana W, Changsan N, Tawithong E, Srichana T. Isoniazid Proliposome Powders for Inhalation-Preparation, Characterization and Cell Culture Studies. International Journal of Molecular Sciences 2011; 12(7):4414-4434.
Parmar JJ, Singh DJ, Hegde DD, Menon M. Development and Evaluation of Inhalational Liposomal System of Budesonide for Better Management of Asthma. Indian Journal of Pharmaceutical Sciences 2010; 72(4):442-448.
Zeng XM, Martin GP, Marriott. The controlled delivery of drugs to the lung. International Journal of Pharmaceutics 1995; 124(2):149–164.
Ugwoke M I, Agu R U, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives, Adv Drug Del Rev 2005; 57.
Shin BN, Chang KK, Shim K. Proliposomes as an intranasal dosage form for the sustained delivery of propranolol. Journal of Controlled Release 1995;34(3): 203-210.
Jung BH, Chung SJ, Shim CK. Proliposomes as prolonged intranasal drug delivery systems. STP Pharma Sci 2002; 12(1): 33-38.
Jung BH, Chung BC, Chung SJ, Shim CK. Prolonged delivery of nicotine in rats via nasal administration of proliposomes. J Control Rel 2000; 66(1):73-79.
Park JM, Ahn BN, Yoon EJ, Lee MG, Shim CK, Kim CK. The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. Biopharm Drug Dispos 1994; 15(5): 391-407.
Katare, OP, Vyas SP, Dixit VK. Effervescent granule based proliposomes of ibuprofen. J Microencapsul 1990; 7(4): 455-460.
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Namita Singh, Poonam Kushwaha, Usama Ahmad, Mohammad Abdullah
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
